Minimal residual disease (MRD)-guided retreatment with anti-CD20 antibodies effectively lowers MRD levels and delays clinical relapse in patients with high-risk chronic lymphocytic leukemia (CLL), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback